Masimo/$MASI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Masimo

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Ticker

$MASI
Sector
Primary listing

Employees

3,600

Masimo Metrics

BasicAdvanced
$8B
-
-$8.54
1.23
-

What the Analysts think about Masimo

Analyst ratings (Buy, Hold, Sell) for Masimo stock.

Bulls say / Bears say

Masimo agreed to sell its Sound United consumer audio business to HARMAN International for $350 million, enabling a strategic refocus on its core professional healthcare segment and freeing capital for innovation in patient monitoring technologies (Reuters).
A U.S. appeals court upheld two earlier ITC decisions favoring Masimo in its patent dispute with Apple over blood-oxygen sensing in smartwatches, reinforcing the company’s intellectual property protections and potential royalty leverage (Reuters).
Masimo’s proprietary SET® pulse-oximetry technology is used on over 200 million patients globally and serves as the primary pulse-oximetry solution at nine of the top ten U.S. hospitals ranked by U.S. News, underscoring its deep market penetration and clinical adoption (FT).
Masimo’s ongoing legal battles have intensified costs and uncertainty after the company sued U.S. Customs for reversing an import ban on Apple Watches featuring disputed pulse-oximetry technology, potentially undermining its ITC exclusion order and prolonging litigation expenses (Reuters).
In Q1 2025, Masimo recorded a GAAP loss from discontinued operations of $218 million—including a $295 million impairment on its consumer audio business—reflecting a significant write-down that weighed heavily on its consolidated results (FT).
A forthcoming U.S. Customs ruling on whether redesigned Apple Watches infringe Masimo’s pulse-oximetry patents threatens to allow Apple to import the contested devices, risking erosion of Masimo’s patent exclusivity and further legal reversals (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

Masimo Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Masimo Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MASI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs